Von willebrand factor ( DrugBank: Von willebrand factor )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
64	血栓性血小板減少性紫斑病	25
288	自己免疫性後天性凝固因子欠乏症	94

64. 血栓性血小板減少性紫斑病

臨床試験数 : 92 / 薬物数 : 85 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 76

diseases per page:

Showing 1 to 10 of 25 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2022-001177-31-DE (EUCTR)	15/09/2022	29/06/2022	Caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults ...	An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and ...	Thrombotic Thrombocytopenic Purpura MedDRA version: 20.0;Level: PT;Classification code 10043648;Term ...	Trade Name: Cablivi® Product Name: Cablivi® Product Code: ALX0081 INN or Proposed INN: Caplacizumab Othe ...	Sanofi-Aventis Recherche & Développement	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	64	Phase 3	United States;Czechia;Greece;Spain;Austria;United Kingdom;Switzerland;Italy;France;Czech Republic;Ca ...
2	EUCTR2016-001503-23-NL (EUCTR)	05/07/2017	19/07/2017	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 20.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand FactorNanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting	Female: yes Male: yes	92	Phase 3	United States;Spain;Turkey;Austria;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Repu ...
3	EUCTR2016-001503-23-DE (EUCTR)	12/04/2017	03/01/2017	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 19.1;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand FactorNanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting	Female: yes Male: yes	92	Phase 3	United States;Spain;Turkey;Austria;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Hun ...
4	EUCTR2016-001503-23-FR (EUCTR)	07/02/2017	20/10/2016	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 19.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand FactorNanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting	Female: yes Male: yes	92	Phase 3	United States;Spain;Turkey;Austria;Israel;United Kingdom;Italy;Switzerland;France;Czech Republic;Hun ...
5	EUCTR2016-001503-23-GB (EUCTR)	15/11/2016	15/08/2016	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 20.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand FactorNanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting	Female: yes Male: yes	104	Phase 3	United States;Spain;Turkey;Austria;Israel;United Kingdom;Italy;Switzerland;France;Czech Republic;Hun ...
6	EUCTR2016-001503-23-CZ (EUCTR)	31/10/2016	19/08/2016	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 20.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand FactorNanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting	Female: yes Male: yes	104	Phase 3	Spain;Turkey;Austria;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Hungary;Canada;Be ...
7	EUCTR2016-001503-23-BE (EUCTR)	21/10/2016	22/08/2016	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 20.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand FactorNanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	104	Phase 3	United States;Spain;Turkey;Austria;Israel;Switzerland;United Kingdom;Italy;France;Czech Republic;Hun ...
8	EUCTR2016-001503-23-HU (EUCTR)	06/10/2016	10/08/2016	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 19.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand FactorNanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting	Female: yes Male: yes	92	Phase 3	United States;Spain;Turkey;Austria;Israel;United Kingdom;Italy;Switzerland;France;Hungary;Czech Repu ...
9	EUCTR2016-001503-23-ES (EUCTR)	25/08/2016	15/07/2016	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 19.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand FactorNanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting	Female: yes Male: yes	92	Phase 3	United States;Spain;Turkey;Austria;Israel;United Kingdom;Italy;Switzerland;France;Czech Republic;Hun ...
10	EUCTR2016-001503-23-AT (EUCTR)	16/08/2016	14/07/2016	Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Lon ...	Acquired thrombotic thrombocytopenic purpura (TTP) MedDRA version: 20.0;Level: PT;Classification cod ...	Product Name: Caplacizumab (an anti-von Willebrand FactorNanobody ALX-0081) Product Code: ALX-0081 INN ...	Ablynx NV	NULL	Not Recruiting	Female: yes Male: yes	104	Phase 3	United States;Spain;Turkey;Austria;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Hun ...

First Previous1 2 3Next Last

先頭へ

288. 自己免疫性後天性凝固因子欠乏症

臨床試験数 : 206 / 薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21

diseases per page:

Showing 1 to 10 of 94 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05582993 (ClinicalTrials.gov)	January 9, 2023	14/10/2022	A Study of Recombinant Von Willebrand Factor(rVWF) (TAK-577) in Children With Severe Von Willebrand ...	A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophy ...	Von Willebrand Disease (VWD)	Biological: Recombinant von Willebrand Factor (rVWF);Biological: ADVATE	Takeda	NULL	Not yet recruiting	N/A	17 Years	All	24	Phase 3	NULL
2	EUCTR2018-004675-13-HR (EUCTR)	28/11/2020	02/12/2020	Study to investigate the study drug (WILATE) in patients with Von Willebrand Disease.	CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF WILATEDURING PROPHYLAXIS IN PREVIOUSLY TREA ...	Von Willebrand disease, type 3, type 2 (except 2N), or severe type 1 MedDRA version: 20.0;Level: LLT ...	Trade Name: Wilate 500 Product Name: Wilate INN or Proposed INN: Human Coagulation Factor VIII, Von Wi ...	Octapharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	28	Phase 3	United States;Belarus;Hungary;Ukraine;Lebanon;Croatia;Russian Federation;Bulgaria
3	EUCTR2019-002023-15-IT (EUCTR)	17/04/2020	17/06/2021	A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc- ...	Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous R ...	severe hemophilia A MedDRA version: 20.0;Level: PT;Classification code 10016080;Term: Factor VIII de ...	Product Name: Recombinant coagulation FVIII Fc – von Willebrand factor– XTEN fusion protein Product C ...	BIOVERATIV THERAPEUTICS INC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	164	Phase 3	United States;Taiwan;Greece;Spain;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argenti ...
4	EUCTR2019-002023-15-DE (EUCTR)	25/02/2020	09/10/2019	A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc- ...	Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous R ...	severe hemophilia A MedDRA version: 20.0;Level: PT;Classification code 10016080;Term: Factor VIII de ...	Product Name: Recombinant coagulation FVIII Fc – von Willebrand factor– XTEN fusion protein Product C ...	Bioverativ Therapeutics Inc. (a Sanofi company)	NULL	Not Recruiting			Female: yes Male: yes	164	Phase 3	United States;Taiwan;Greece;Spain;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argenti ...
5	EUCTR2019-002023-15-FR (EUCTR)	06/02/2020	04/11/2019	A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc- ...	Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous R ...	severe hemophilia A MedDRA version: 20.0;Level: PT;Classification code 10016080;Term: Factor VIII de ...	Product Name: Recombinant coagulation FVIII Fc – von Willebrand factor– XTEN fusion protein Product C ...	Bioverativ Therapeutics Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	164	Phase 3	Colombia;Argentina;Hungary;United States;Japan;United Kingdom;Spain;Greece;Canada;Netherlands;Belgiu ...
6	EUCTR2019-002023-15-ES (EUCTR)	28/01/2020	02/12/2019	A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc- ...	Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous R ...	Severe hemophilia A MedDRA version: 20.0;Level: PT;Classification code 10016080;Term: Factor VIII de ...	Product Name: Recombinant coagulation FVIII Fc – von Willebrand factor– XTEN fusion protein Product C ...	Bioverativ Therapeutics Inc.	NULL	Not Recruiting			Female: yes Male: yes	164	Phase 3	United States;Taiwan;Greece;Spain;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argenti ...
7	EUCTR2019-002023-15-BG (EUCTR)	22/01/2020	06/11/2019	A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc- ...	Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous R ...	severe hemophilia A MedDRA version: 20.0;Level: PT;Classification code 10016080;Term: Factor VIII de ...	Product Name: Recombinant coagulation FVIII Fc – von Willebrand factor– XTEN fusion protein Product C ...	Bioverativ Therapeutics Inc. (a Sanofi company)	NULL	Not Recruiting			Female: yes Male: yes	164	Phase 3	United States;Taiwan;Greece;Spain;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argenti ...
8	EUCTR2019-002023-15-HU (EUCTR)	21/01/2020	20/11/2019	A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc- ...	Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous R ...	severe hemophilia A MedDRA version: 20.0;Level: PT;Classification code 10016080;Term: Factor VIII de ...	Product Name: Recombinant coagulation FVIII Fc – von Willebrand factor– XTEN fusion protein Product C ...	Bioverativ Therapeutics Inc.	NULL	Not Recruiting			Female: yes Male: yes	164	Phase 3	United States;Taiwan;Greece;Spain;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argenti ...
9	EUCTR2019-002023-15-GB (EUCTR)	06/01/2020	10/10/2019	NA Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc ...	Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous R ...	Severe hemophilia A MedDRA version: 20.0;Level: PT;Classification code 10016080;Term: Factor VIII de ...	Product Name: Recombinant coagulation FVIII Fc – von Willebrand factor– XTEN fusion protein Product C ...	Bioverativ Therapeutics Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	164	Phase 3	Argentina;Hungary;United States;Japan;United Kingdom;Spain;Greece;Canada;Netherlands;Belgium;Taiwan; ...
10	EUCTR2019-002023-15-GR (EUCTR)	27/12/2019	13/11/2019	A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc- ...	Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous R ...	Severe hemophilia A MedDRA version: 20.0;Level: PT;Classification code 10016080;Term: Factor VIII de ...	Product Name: Recombinant coagulation FVIII Fc – von Willebrand factor– XTEN fusion protein Product C ...	Bioverativ Therapeutics Inc. (a Sanofi company)	NULL	Not Recruiting			Female: yes Male: yes	164	Phase 3	United States;Taiwan;Greece;Spain;Colombia;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argenti ...

First Previous1 2 3 4 5…10Next Last

先頭へ